514 related articles for article (PubMed ID: 16193235)
1. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
[TBL] [Abstract][Full Text] [Related]
2. Alteration of newly induced endochondral bone formation in adult mice without tumour necrosis factor receptor 1.
Lukić IK; Grcević D; Kovacić N; Katavić V; Ivcević S; Kalajzić I; Marusić A
Clin Exp Immunol; 2005 Feb; 139(2):236-44. PubMed ID: 15654822
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines.
Hofbauer LC; Dunstan CR; Spelsberg TC; Riggs BL; Khosla S
Biochem Biophys Res Commun; 1998 Sep; 250(3):776-81. PubMed ID: 9784422
[TBL] [Abstract][Full Text] [Related]
4. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate treatment increases the size of the mandibular condyle and normalizes growth of the mandibular ramus in osteoprotegerin-deficient mice.
Kimura M; Miyazawa K; Tabuchi M; Maeda H; Kameyama Y; Goto S
Calcif Tissue Int; 2008 Feb; 82(2):137-47. PubMed ID: 18183447
[TBL] [Abstract][Full Text] [Related]
6. Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption.
Onyia JE; Galvin RJ; Ma YL; Halladay DL; Miles RR; Yang X; Fuson T; Cain RL; Zeng QQ; Chandrasekhar S; Emkey R; Xu Y; Thirunavukkarasu K; Bryant HU; Martin TJ
J Pharmacol Exp Ther; 2004 Apr; 309(1):369-79. PubMed ID: 14718597
[TBL] [Abstract][Full Text] [Related]
7. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Kaji H; Kanatani M; Sugimoto T; Chihara K
Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
[TBL] [Abstract][Full Text] [Related]
8. Regulation of secretion of osteoprotegerin in rat dental follicle cells.
Wise GE; Ding D; Yao S
Eur J Oral Sci; 2004 Oct; 112(5):439-44. PubMed ID: 15458504
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin in prostate cancer bone metastasis.
Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.
Nakamura M; Udagawa N; Matsuura S; Mogi M; Nakamura H; Horiuchi H; Saito N; Hiraoka BY; Kobayashi Y; Takaoka K; Ozawa H; Miyazawa H; Takahashi N
Endocrinology; 2003 Dec; 144(12):5441-9. PubMed ID: 14500574
[TBL] [Abstract][Full Text] [Related]
11. Bone morphogenetic proteins 5 and 6 stimulate osteoclast generation.
Wutzl A; Brozek W; Lernbass I; Rauner M; Hofbauer G; Schopper C; Watzinger F; Peterlik M; Pietschmann P
J Biomed Mater Res A; 2006 Apr; 77(1):75-83. PubMed ID: 16355411
[TBL] [Abstract][Full Text] [Related]
12. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
13. Biglycan deficiency interferes with ovariectomy-induced bone loss.
Nielsen KL; Allen MR; Bloomfield SA; Andersen TL; Chen XD; Poulsen HS; Young MF; Heegaard AM
J Bone Miner Res; 2003 Dec; 18(12):2152-8. PubMed ID: 14672350
[TBL] [Abstract][Full Text] [Related]
14. Suppression of polyethylene particle-induced osteolysis by exogenous osteoprotegerin.
von Knoch F; Heckelei A; Wedemeyer C; Saxler G; Hilken G; Brankamp J; Sterner T; Landgraeber S; Henschke F; Löer F; von Knoch M
J Biomed Mater Res A; 2005 Nov; 75(2):288-94. PubMed ID: 16088891
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.
Kostenuik PJ; Bolon B; Morony S; Daris M; Geng Z; Carter C; Sheng J
Bone; 2004 Apr; 34(4):656-64. PubMed ID: 15050896
[TBL] [Abstract][Full Text] [Related]
16. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
Saidenberg-Kermanac'h N; Corrado A; Lemeiter D; deVernejoul MC; Boissier MC; Cohen-Solal ME
Bone; 2004 Nov; 35(5):1200-7. PubMed ID: 15542046
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
Schett G; Redlich K; Hayer S; Zwerina J; Bolon B; Dunstan C; Görtz B; Schulz A; Bergmeister H; Kollias G; Steiner G; Smolen JS
Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
[TBL] [Abstract][Full Text] [Related]
18. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice.
Schindeler A; Ramachandran M; Godfrey C; Morse A; McDonald M; Mikulec K; Little DG
J Orthop Res; 2008 Jan; 26(1):65-74. PubMed ID: 17787010
[TBL] [Abstract][Full Text] [Related]
19. Synergistic enhancement of new bone formation by recombinant human bone morphogenetic protein-2 and osteoprotegerin in trans-sutural distraction osteogenesis: a pilot study in dogs.
Yao Y; Wang G; Wang Z; Wang C; Zhang H; Liu C
J Oral Maxillofac Surg; 2011 Nov; 69(11):e446-55. PubMed ID: 22018252
[TBL] [Abstract][Full Text] [Related]
20. Regulation of BMP-induced ectopic bone formation by Ahsg.
Rittenberg B; Partridge E; Baker G; Clokie C; Zohar R; Dennis JW; Tenenbaum HC
J Orthop Res; 2005 May; 23(3):653-62. PubMed ID: 15885488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
